Document Type

Article

Publication Date

2025

DOI

10.1016/j.anai.2025.06.018

Publication Title

Annals of Allergy, Asthma & Immunology

Volume

135

Issue

3

Pages

336-338

Abstract

[Introduction] Chronic rhinosinusitis with nasal polyps (CRSwNP) can substantially affect quality of life (QoL), and is often challenging to manage.¹ First-line treatment for the management of CRSwNP involves intranasal corticosteroids, with short courses of systemic corticosteroids (SCS) for exacerbations, and sinus surgery for uncontrolled disease.² Biologics targeting type 2 inflammation (eg, dupilumab, omalizumab, and mepolizumab) have become a treatment option for refractory CRSwNP. With the advent of disease-modifying treatments such as biologics, control, defined as patients reporting no/low-symptom levels, has increasingly become the treatment goal for CRSwNP.³ However, the optimal use of biologics for symptom control in individual patients remains unclear, and the heterogeneity of study populations, designs, and tools used across phase III trials makes comparisons difficult.

Rights

© 2025 American College of Allergy, Asthma & Immunology.

This is an open access article under the Creative Commons Attribution 4.0 International (CC BY 4.0) License.

Data Availability

Article states: "Please refer to GSK weblink to access GSK’s data sharing policies, and as applicable seek anonymized subject level data by means of the link https://www.gsk-studyregister.com/en/"

Original Publication Citation

Hopkins, C., Borish, L., Silver, J., Howarth, P., Chan, R., Dsilva, P., & Han, J. K. (2025). Categorizing clinical response to mepolizumab for patients with chronic rhinosinusitis with nasal polyps: SYNAPSE trial. Annals of Allergy, Asthma & Immunology, 135(3), 336-338. https://doi.org/10.1016/j.anai.2025.06.018

Download

Share

COinS